

Blockbuster Drugs Market: Global Industry Analysis and Opportunity Assessment, 2019 – 2025

The global 50 blockbuster drugs market size is estimated to reach a value of US\$ 292 billion by 2025.

PUNE , MAHARASHTRA, INDIA, February 28, 2019 /EINPresswire.com/ -- [Global Blockbuster Drugs Industry](#)

The global 50 blockbuster drugs market size is estimated to reach a value of US\$ 292 billion by 2025.

“Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for global blockbuster drugs market. The report includes historic data from 2015 to 2017 and forecasts until 2025.

Try Sample Report @ <https://www.wiseguyreports.com/sample-request/3602067-global-blockbuster-drugs-market-2015-2025-top-50>

The report contains a granular analysis of the present industry situations, market demands, reveals facts on the market size, revenues and provides forecasts through 2025. The report provides clear insight into current and future developments of the global blockbuster drugs market. The report explores detailed analysis of top 50 drugs market assessment globally from 2015 to 2017 and forecasts to 2025. The report also details the latest information about the global research & development spend by pharma & biotech companies

Additionally, the report includes assessment of most valuable drugs research and development projects insights by phase and market value. Key trends in terms of collaboration, merger & acquisition, partnerships and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the global blockbuster drugs market.

The report concludes with the profiles of major players in the global blockbuster drugs market. The key market players are evaluated on various parameters such as business overview and recent development.

The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

- 1) AbbVie
- 2) Celgene
- 3) Gilead Science
- 4) Merck
- 5) Roche

- 6) Bristol-Myers Squibb
- 7) Pfizer
- 8) Johnson & Johnson
- 9) Amgen
- 10) Biogen
- 11) Bayer
- 12) Regeneron Pharmaceuticals
- 13) Novo Nordisk
- 14) Allergan
- 15) Alexion Pharmaceuticals
- 16) GlaxoSmithKline
- 17) Novartis
- 18) Eli Lilly and Company
- 19) AstraZeneca
- 20) Incyte Corporation
- 21) Boehringer Ingelheim
- 22) Astellas Pharma

Top 50 Blockbuster Drugs Covered Under This Report Are:

- 1) Humira
- 2) Imbruvica
- 3) Revlimid
- 4) Genvoya
- 5) Truvada
- 6) Harvoni
- 7) Epclusa
- 8) Keytruda
- 9) Januvia/Janumet
- 10) Herceptin
- 11) Avastin
- 12) MabThera/Rituxan
- 13) Perjeta
- 14) Opdivo
- 15) Eliquis
- 16) Orencia
- 17) Sprycel
- 18) Lyrica
- 19) Ibrance
- 20) Simponi
- 21) Stelara
- 22) Zytiga
- 23) Invega Sustenna
- 24) Xarelto
- 25) Enbrel
- 26) Tagrisso
- 27) Tecfidera
- 28) Eylea
- 29) Victoza
- 30) Botox
- 31) Soliris
- 32) Triumeq
- 33) Seretide/Advair
- 34) Gilenya
- 35) Cosentyx
- 36) Trulicity

- 37) Cialis
- 38) Humalog
- 39) Symbicort
- 40) Zepatier
- 41) Pomalyst/Imnovid
- 42) Darzalex
- 43) Prolia/Xgeva
- 44) Ocrevus
- 45) Xtandi
- 46) Tivicay
- 47) Jakafi/Jakavi
- 48) Jardiance
- 49) Trajenta / Jentadueto
- 50) Relvar/Breo Ellipta

The Latest Industry Data Included in this Report:

Global Top 50 Blockbuster Drugs Market Size & Analysis (2015 – 2025)
Global Top 50 Blockbuster Drugs Market Share & Y-o-Y Growth (%), 2015 – 2025
Global Top 50 Blockbuster Drugs Market Assessment & Opportunity, (2015 – 2025)
Most Valuable Drugs Research and Development (R&D) Projects Insights by Phase and Market Value
Global Research & Development (R&D) Spend by Pharma & Biotech Companies (2015 – 2025)
Major Deals (Mergers, Acquisitions, Key Agreements, Partnerships & Collaborations)
Key Market Drivers and Inhibitors of the Global Blockbuster Drugs Market
Major Companies Analysis

The Answers to the Following Key Questions can be found in the Report:

What is the size of the global top 50 blockbuster drugs market during 2015 -2025?
What will be the revenue generated by each drug during the forecast period?
Which major drugs provides highest market share?
How are the overall market and major drugs growing?
What are the key drivers and inhibitors in the current market?
What will be the impact of drivers and inhibitors in the future?
How is the market predicted to develop in the future?
Who are the key players in this market space?

For Detailed Reading Please visit WiseGuy Reports @

<https://www.wiseguyreports.com/reports/3602067-global-blockbuster-drugs-market-2015-2025-top-50>

Some Major Points from Table of content:

Executive Summary
Global Top 50 Blockbuster Drugs Market Size& Analysis (2015 – 2025)
Global Top 50 Blockbuster Drugs Market Share & Y-o-Y Growth (%), 2015 – 2025
Key Drivers and Inhibitors of the Global Blockbuster Drugs Market
4.1 Market Drivers
4.2 Market Inhibitors
Global Top 50 Blockbuster Drugs Market Assessment & Opportunity, (2015 – 2025)
5.1 Humira (Adalimumab)
5.2 Imbruvica (Ibrutinib)
5.3 Revlimid (Lenalidomide)
5.4 Pomalyst/Imnovid (Pomalidomide)
5.5 Genvoya (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide fumarate)

- 5.6 Truvada (Emtricitabine / Tenofovir)
- 5.7 Harvoni (Ledipasvir / Sofosbuvir)
- 5.8 Epclusa (Sofosbuvir / Velpatasvir)
- 5.9 Keytruda (Pembrolizumab)
- 5.10 Januvia/Janumet (Sitagliptin / Metformin)
- 5.11 Herceptin (Trastuzumab)
- 5.12 Avastin (Bevacizumab)
- 5.13 MabThera/Rituxan (Rituximab)
- 5.14 Perjeta (Pertuzumab)
- 5.15 Opdivo (Nivolumab)
- 5.16 Eliquis (Apixaban)
- 5.17 Orenzia (Abatacept)
- 5.18 Sprycel (Dasatinib)
- 5.19 Lyrica (Pregabalin)
- 5.20 Ibrance (Palbociclib)
- 5.21 Simponi (Golimumab)
- 5.22 Stelara (Ustekinumab)
- 5.23 Zytiga (Abiraterone acetate)
- 5.24 Invega Sustenna (Paliperidone)
- 5.25 Xarelto (Rivaroxaban)
- 5.26 Tagrisso (Osimertinib)
- 5.27 Enbrel (Etanercept)
- 5.28 Eylea (Aflibercept)
- 5.29 Victoza (Liraglutide)
- 5.30 Botox (Botulinum toxin)
- 5.31 Soliris (Eculizumab)
- 5.32 Triumeq (Abacavir / Dolutegravir / Lamivudine)
- 5.33 Seretide/Advair (Fluticasone propionate / Salmeterol)
- 5.34 Gilenya (Fingolimod)
- 5.35 Cosentyx (Secukinumab)
- 5.36 Trulicity (Dulaglutide)
- 5.37 Humalog (Insulin Lispro)
- 5.38 Cialis (Tadalafil)
- 5.39 Symbicort (Budesonide / Formoterol)
- 5.40 Zepatier (Elbasvir / Grazoprevir)
- 5.41 Tecfidera (Dimethyl fumarate)
- 5.42 Darzalex (Daratumumab)
- 5.43 Prolia/Xgeva (Denosumab)
- 5.44 Ocrevus (Ocrelizumab)
- 5.45 Xtandi (Enzalutamide)
- 5.46 Tivicay (Dolutegravir)
- 5.47 Jakafi/Jakavi (Ruxolitinib Phosphate)
- 5.48 Jardiance (Empagliflozin)
- 5.49 Trajenta/Jentadueto (Linagliptin)
- 5.50 Relvar/Breo Ellipta (Fluticasone furoate / Vilanterol)

Most Valuable Drugs Research and Development (R&D) Projects Insights by Phase and Market Value

Global Research & Development (R&D) Spend by Pharma & Biotech Companies (2015 – 2025)
Major Deals (Mergers, Acquisitions, Key Agreements, Partnerships & Collaborations)

Continued...

For more information or any query mail at sales@wiseguyreports.com

Norah Trent
WISEGUY RESEARCH CONSULTANTS PVT LTD

8411985042
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.